prostate cancer

43 all articles · 20 / page

Ask MedXY AI

Latest news

Tag

All articles

Balancing Benefit and Harm: How Long Should Androgen Deprivation Therapy Be Given With Radiotherapy for Localized Prostate Cancer?

An individual-patient data meta-analysis of 10,266 men shows nonlinear oncologic benefit from longer ADT with radiotherapy (diminishing beyond 9–12 months) but increasing other-cause mortality with long-term ADT; optimal duration should be

Section: newsNov 24, 2025

Metformin Fails to Delay Progression on Active Surveillance for Low‑Risk Prostate Cancer — Unexpected Signal in Obese Men

The MAST phase III trial found no benefit of metformin (850 mg twice daily) versus placebo for delaying progression in men with low‑risk prostate cancer on active surveillance; a prespecified subgroup showed increased pathologic progression

prostate cancer

Latest news

Balancing Benefit and Harm: How Long Should Androgen Deprivation Therapy Be Given With Radiotherapy for Localized Prostate Cancer?

Metformin Fails to Delay Progression on Active Surveillance for Low‑Risk Prostate Cancer — Unexpected Signal in Obese Men

Metformin Does Not Delay Progression on Active Surveillance for Low‑Risk Prostate Cancer — Unexpected Signal in Obesity

Metformin in Metastatic Hormone-Sensitive Prostate Cancer Undergoing Androgen Deprivation Therapy: Insights from the STAMPEDE Phase 3 Trial and Contemporary Evidence

Metformin Did Not Prevent Metabolic Syndrome During ADT but Improved Weight, Waist and HbA1c: Findings from the PRIME Phase 3 Trial

Comprehensive Overview of the AMPLITUDE Trial Results on Niraparib and AAP in HRR-Deficient Prostate Cancer

Talazoparib plus Enzalutamide Significantly Prolongs Survival in mCRPC: Final TALAPRO-2 Results Confirm Greatest Benefit in BRCA‑Altered Disease

European Prostate Cancer Screening After 23 Years: Sustained Mortality Reduction and Improved Harm-Benefit Profile

Age-Dependent Benefits of Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer: A Comprehensive Meta-Analysis

Rethinking Gleason Grade Group 1 Prostate Cancer: Insights from a Large-Scale Cohort Study

Enhancing Survival in Biochemically Recurrent Prostate Cancer: The Promising Role of Enzalutamide

Cribriform Morphology’s Impact on Long-term Metastasis Risk in Prostate Cancer: Insights from the PROTECT Trial

Biparametric MRI Matches Multiparametric MRI for Prostate Cancer Diagnosis: Insights from the PRIME Trial

PSMA PET-Guided Intensification of Salvage Radiotherapy Enhances Outcomes Post-Radical Prostatectomy: Insights from a Phase 2 RCT

How Often Should Men Have Sex? Harvard Study Links 21 Times a Month to Lower Prostate Cancer Risk

AI Foundation Model Revolutionizes Non-Invasive Diagnosis and Grading of Prostate Cancer

Frequent Ejaculation and Prostate Cancer Risk: Insights from a Landmark Harvard Study

Statin Use and Survival Benefits in Advanced Prostate Cancer Patients Receiving Apalutamide: Insights from the TITAN and SPARTAN Trials

FDA Approves ArteraAI Prostate: The First AI-Driven Software Transforming Localized Prostate Cancer Management

KEYNOTE-991: Pembrolizumab Does Not Improve Outcomes in Metastatic Hormone-Sensitive Prostate Cancer—A Phase III Clinical Trial Analysis